Moguisteine (R,S(+/-)-2-(2-methoxyphenoxy)-methyl-3- ethoxycarbonylace
tyl-1,3-thiazolidine, CAS 119637-67-1), a new oral non narcotic periph
erally acting antitussive drug, was examined for effects in the rat on
general reproductive performance (at 0, 50, 212, 900 mg/kg/d,) for em
bryotoxicity (at 0, 25, 75, 225, 900 mg/kg/d) and for peri-postnatal t
oxicity (at 0, 62.5, 250), 1000 mg/kg/d). Embryotoxicity (at 0, 75, 22
5, 900 mg/kg/d) was also examined in the New Zealand White rabbit. In
all the studies moguisteine was administered orally as a suspension by
gavage. At the tested doses, moguisteine did not interfere with gener
al reproductive performance, either in the F0 or in the F1 generation.
The drug did not show any toxic effect on the dams and their fetuses,
nor did it have any teratogenic effect in either of the tested specie
s. Finally moguisteine had no adverse effects either on parturition or
on peri- and postnatal survival and/or development of the offspring.